Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.78)
# 2351
Out of 5,370 analysts
36
Total ratings
54.55%
Success rate
-1.51%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BPMC Blueprint Medicines | Downgrades: Equal-Weight | 150 135 | 128.09 | 5.39% | 3 | Jun 3, 2025 | |
ELEV Elevation Oncology | Downgrades: Equal-Weight | 5 5 | n/a | n/a | 4 | Mar 24, 2025 | |
IMNM Immunome | Reiterates: Overweight | 30 30 | 9.54 | 214.47% | 2 | Mar 20, 2025 | |
CPRX Catalyst Pharmaceuti... | Reiterates: Overweight | 33 33 | 23.66 | 39.48% | 2 | Feb 27, 2025 | |
ADCT ADC Therapeutics | Maintains: Overweight | 6 8 | 3.35 | 138.81% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 50 50 | 22.4 | 123.21% | 2 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Equal-Weight | 29 29 | 41.74 | -30.52% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Equal-Weight | 15 15 | 8.04 | 86.57% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 31 31 | 11.87 | 161.16% | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 60 60 | 46.85 | 28.07% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 5 5 | 1.52 | 228.95% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 4 | 1.63 | 145.4% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 55 | 7.38 | 645.26% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 13 | 1.21 | 974.38% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 25 25 | 15.39 | 62.44% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 100 100 | n/a | n/a | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 2 | 900% | 1 | May 14, 2024 |